Literature DB >> 16209896

Dose-response in stereotactic irradiation of lung tumors.

Joern Wulf1, Kurt Baier, Gerd Mueller, Michael P Flentje.   

Abstract

The dose-response for local tumor control after stereotactic radiotherapy of 92 pulmonary tumors (36 NSCLC and 56 metastases) was evaluated. Short course irradiation of 1-8 fractions with different fraction doses was used. After a median follow-up of 14 months (2-85 months) 11 local recurrences were observed with significant advantage for higher doses. When normalization to a biologically effective dose (BED) is used a dose of 94Gy at the isocenter and 50Gy at the PTV-margin are demonstrated to give 50% probability of tumor control (TCD50). Multivariate analysis revealed the dose at the PTV-margin as the only significant factor for local control.

Entities:  

Mesh:

Year:  2005        PMID: 16209896     DOI: 10.1016/j.radonc.2005.09.003

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  46 in total

Review 1.  Radiation dose effect in locally advanced non-small cell lung cancer.

Authors:  Feng-Ming Spring Kong; Jing Zhao; Jingbo Wang; Corrine Faivre-Finn
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.

Authors:  Daniel H Schanne; Ursula Nestle; Michael Allgäuer; Nicolaus Andratschke; Steffen Appold; Ute Dieckmann; Iris Ernst; Ute Ganswindt; Anca L Grosu; Richard Holy; Michael Molls; Meinhard Nevinny-Stickel; Sabine Semrau; Florian Sterzing; Andrea Wittig; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-08-27       Impact factor: 3.621

Review 3.  Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Authors:  Meghan Campo; Hani Al-Halabi; Melin Khandekar; Alice T Shaw; Lecia V Sequist; Henning Willers
Journal:  Oncologist       Date:  2016-06-27

4.  Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model.

Authors:  Barbara Diletto; Nicola Dinapoli; Silvia Chiesa; Gian Carlo Mattiucci; Vincenzo Frascino; Carmelo Anile; Cesare Colosimo; Vincenzo Valentini; Mario Balducci
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 5.  The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer.

Authors:  Zhengfei Zhu; Xiaolong Fu
Journal:  Transl Lung Cancer Res       Date:  2015-06

Review 6.  [Radiation therapy of lung carcinoma].

Authors:  S Oertel; J Debus; H Hof; M Bischof
Journal:  Radiologe       Date:  2010-08       Impact factor: 0.635

7.  Effects of the recurrence pattern on patient survival following SABR for stage I lung cancer.

Authors:  Elisabeth Weiss; Xiaoyan Deng; Nitai Mukhopadhyay; Nuzhat Jan
Journal:  Acta Oncol       Date:  2020-01-12       Impact factor: 4.089

Review 8.  The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?

Authors:  Gregory M M Videtic; Kevin L Stephans
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

9.  Management of three-dimensional intrafraction motion through real-time DMLC tracking.

Authors:  Amit Sawant; Raghu Venkat; Vikram Srivastava; David Carlson; Sergey Povzner; Herb Cattell; Paul Keall
Journal:  Med Phys       Date:  2008-05       Impact factor: 4.071

10.  An evaluation of planning techniques for stereotactic body radiation therapy in lung tumors.

Authors:  Jianzhou Wu; Huiling Li; Raj Shekhar; Mohan Suntharalingam; Warren D'Souza
Journal:  Radiother Oncol       Date:  2008-03-24       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.